Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Isosulfan Blue Inner Salt. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 11/20 | 0.39 |
| ▸ | CNR1 | P21554 | 8/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL340854 | 0.90 | MEN1 (0.44) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL124487 | 0.80 | THRB (0.50) | MEN1KMT2AALDH1A1MAPTBLM | |
| SCHEMBL340120 | 0.80 | MEN1 (0.40) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL341270 | 0.79 | THRB (0.45) | MEN1KMT2AALDH1A1MAPTCNR2 | |
| SCHEMBL20740546 | 0.77 | THRB (0.48) | MEN1KMT2AALDH1A1MAPTBLM | |
| SCHEMBL2859639 | 0.76 | THRB (0.53) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL126069 | 0.74 | THRB (0.47) | MEN1KMT2AALDH1A1MAPTBLM | |
| SCHEMBL31244568 | 0.74 | ALDH1A1 (0.44) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL4019433 | 0.74 | ALDH1A1 (0.44) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL2868709 | 0.73 | THRB (0.53) | MEN1KMT2AL3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0743523-B1 | Dye-based reference material, preparation and use thereof | BAYER AG (US) | 2002-08-28 | — | — | EP | claimed |
| US-20250270168-A1 | SYNTHESIS PROCESS FOR HIGH PURITY ISOSULFAN BLUE USING FLASH CHROMATOGRAPHY IN COMMERCIAL PLANT SCALE | RISING PHARMA HOLDINGS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250195439-A1 | METHOD FOR TREATING LOCAL LESION DISEASE | CHENGDU KUACHANGAOPU MEDICAL TECHNOLOGY CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| EP-3845247-B1 | USE OF AMINO ACID BASED NUTRIENTS AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CHENGDU KUACHANGAOPU MEDICAL TECH CO LTD (CN) | 2025-06-04 | — | — | EP | disclosed |
| US-12180142-B1 | Synthesis process for high purity isosulfan blue using flash chromatography in commercial plant scale | RISING PHARMA HOLDINGS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4132906-B1 | PROCESS FOR SYNTHESIZING SULFONATED TRIARYL METHANE COMPOUNDS | PROVEPHARM LIFE SOLUTIONS (FR) | 2024-05-15 | — | — | EP | disclosed |
| EP-4132905-B1 | PROCESS FOR SYNTHESIZING SULFONATED TRIARYL METHANE COMPOUNDS | PROVEPHARM LIFE SOLUTIONS (FR) | 2024-05-15 | — | — | EP | disclosed |
| EP-4361127-A2 | PROCESS FOR THE SYNTHESIS OF SULFONATED TRIARYLMETHANE COMPOUNDS | Provepharm Life Solutions (FR) | 2024-05-01 | — | — | EP | disclosed |
| US-20230348372-A1 | PROCESS FOR SYNTHESIZING TRIARYLMETHANE SULFONE COMPOUNDS | PROVEPHARM LIFE SOLUTIONS (FR) | 2023-11-02 | — | — | US | disclosed |
| US-20230159444-A1 | PROCESS FOR SYNTHESIZING SULFONATED TRIARYL METHANE COMPOUNDS | PROVEPHARM LIFE SOLUTIONS (FR) | 2023-05-25 | — | — | US | disclosed |
| CN-107569512-A | Medical composition and its use comprising quinine class compound and metallic compound | 成都夸常科技有限公司 | 2018-01-12 | — | — | CN | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| US-8597613-B2 | Radiolabeled lymphatic staining agents and methods for making | Iso-Tex Diagnostics, Inc (US) | 2013-12-03 | — | — | US | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-20100119447-A1 | Radiolabeled lymphatic staining agents and methods for making | MALONEY THOMAS J | 2010-05-13 | — | — | US | disclosed |
| US-20080008658-A1 | Contrast Agent Formulations for the Visualization of the Lymphatic System | BRACCO IMAGING SPA (IT) | 2008-01-10 | — | — | US | disclosed |
| EP-1796734-A1 | CONTRAST AGENT FORMULATIONS FOR THE VISUALIZATION OF THE LYMPHATIC SYSTEM | Bracco Imaging, S.P.A. (IT) | 2007-06-20 | — | — | EP | disclosed |
| EP-1655040-A1 | Contrast agent formulations for the visualization of the lymphatic system | Bracco Imaging, S.P.A. (IT) | 2006-05-10 | — | — | EP | disclosed |
| WO-2006037803-A1 | CONTRAST AGENT FORMULATIONS FOR THE VISUALIZATION OF THE LYMPHATIC SYSTEM | BRACCO IMAGING SPA (IT) | 2006-04-13 | — | — | WO | disclosed |
| US-20060002850-A1 | Radiolabeled lymphatic staining agents and methods for making | ISO-TEX DIAGNOSTICS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270168-A1 | SYNTHESIS PROCESS FOR HIGH PURITY ISOSULFAN BLUE USING FLASH CHROMATOGRAPHY IN COMMERCIAL PLANT SCALE | CBS, SLC6A12, RPS4Y1 | PPARG 4562/4885MEN1 2901/4885KMT2A 3402/4885 |
| US-12180142-B1 | Synthesis process for high purity isosulfan blue using flash chromatography in commercial plant scale | CBS, SLC6A12, RPS4Y1 | PPARG 4562/4885MEN1 2901/4885KMT2A 3402/4885 |
| US-20230348372-A1 | PROCESS FOR SYNTHESIZING TRIARYLMETHANE SULFONE COMPOUNDS | TST, SQOR, SDHA | PPARG 1758/4885MEN1 3500/4885KMT2A 2233/4885 |
| US-20230159444-A1 | PROCESS FOR SYNTHESIZING SULFONATED TRIARYL METHANE COMPOUNDS | SQOR, SULT1E1, TST | PPARG 2979/4885MEN1 914/4885KMT2A 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.